Ignite Creation Date:
2024-05-06 @ 8:23 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06366425
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-17
First Post:
2024-03-22
Brief Title:
Screening for Chronic Liver Diseases in General Population
Sponsor:
University Hospital Montpellier
Organization:
University Hospital Montpellier
Study Overview
Official Title:
Non-invasive Screening for Chronic Liver Diseases in the General Population A Prospective Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HEPGEN
Brief Summary:
Improving the care of patients with liver diseases in primary care and will allow patients with chronic liver disease to benefit from a course appropriate care
Detailed Description:
The prevalence of chronic liver diseases continues to increase on the one hand by the increase in non-alcoholic fatty liver disease NAFLD which affects 25 of the general population as well as the increased incidence of hepatocellular carcinoma in recent years Screening for liver fibrosis in the general population represents a major public health issue
The FIB-4 score is obtained by a blood test This score combines age measurement of ALTASAT alanine aminotransferase aspartate-aminotransferase and platelet count This score is sensitive for detecting advanced fibrosis liver and allows 71 of patients to avoid a liver biopsy
Transient elastometry Fibroscan is another very effective non-invasive assessment in the diagnosis of chronic liver diseases and hepatic fibrosis It has already been demonstrated by several studies that combining several non-invasive fibrosis tests allows to improve the precision of the result
The investigators hypothesize that offering an additional assessment by Fibroscan for patients screened by a blood test FIB-4 Score as possibly having advanced liver fibrosis Score 267 will raise awareness among professional practitioners and the general population with chronic liver diseases and refine screening for chronic liver diseases
The FIB-4 score is obtained by a blood test This score combines age measurement of ALTASAT alanine aminotransferase aspartate-aminotransferase and platelet count This score is sensitive for detecting advanced fibrosis liver and allows 71 of patients to avoid a liver biopsy
Transient elastometry Fibroscan is another very effective non-invasive assessment in the diagnosis of chronic liver diseases and hepatic fibrosis It has already been demonstrated by several studies that combining several non-invasive fibrosis tests allows to improve the precision of the result
The investigators hypothesize that offering an additional assessment by Fibroscan for patients screened by a blood test FIB-4 Score as possibly having advanced liver fibrosis Score 267 will raise awareness among professional practitioners and the general population with chronic liver diseases and refine screening for chronic liver diseases
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None